Parexel Biotech and RenovoRx Reach Key Milestone in Pancreatic Cancer Clinical Trial for Locally-Advanced Pancreatic Cancer
RenovoRx, Inc., an innovator in targeted cancer therapy, and Parexel Biotech, a division of Parexel, one of the world’s leading global clinical research organizations (CROs) focused on accelerating the development and delivery of innovative new therapies to improve world health, today announced the TIGeR-PaC Phase III clinical trial of Trans-Arterial Micro-Perfusion (TAMPTM) has reached its first patient enrolled in Europe. Overall trial enrollment is on schedule and is exceeding 20 percent worldwide.
Parexel Biotech and RenovoRx Reach Key Milestone in Pancreatic Cancer Clinical Trial for Locally-Advanced Pancreatic Cancer
RenovoRx and Parexel Biotech, a division of Parexel, one of the world’s leading global clinical research organizations (CROs) focused on accelerating the development and delivery of innovative new therapies to improve world health, today announced the TIGeR-PaC Phase III clinical trial of Trans-Arterial Micro-Perfusion (TAMPTM) has reached its first patient enrolled in Europe. Overall trial enrollment is on schedule and is exceeding 20 percent worldwide.